查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1461371

白塞氏症治療藥物市場：現況分析與預測（2023-2030）

Behcet's Disease Therapeutics Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 137 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

由於白塞氏症在全球的盛行率不斷增加，白塞氏症治療藥物市場預計將以約 5.1% 的速度穩定成長。 例如，根據國家罕見疾病組織的數據，白塞氏症最常見於中東和亞洲。 土耳其的盛行率最高，日本、韓國、中國、伊朗和沙烏地阿拉伯的盛行率也很高。 它是日本第一大失明原因。 在預測期內，有幾個因素正在推動市場成長，包括尋找有效治療方法的臨床試驗數量的增加以及醫療保健行業投資的增加。 除此之外，白塞氏症藥物診斷的加速增加了對有效治療方法的需求，這也正在穩步推動白塞氏症藥物市場。

依治療，市場分為皮質類固醇、免疫抑制劑等。 由於嚴重白塞氏症患者的增加，免疫抑制劑領域在 2022 年佔市場主導地位。 免疫抑制劑是白塞氏症治療方案的重要組成部分，適用於單獨使用皮質類固醇治療效果不佳或需要長期治療以防止病情發作的患者。 這些藥物的作用是抑制導致白塞氏症發炎的過度免疫反應。 因此，2022年，免疫抑制劑領域將在治療藥物中佔有較大的市場佔有率。

依給藥途徑，市場分為口服製劑、注射製劑等。 由於臨床試驗數量不斷增加，預計注射劑市場在預測期內將以高複合年增長率成長。 例如，2023年1月，索哈格大學在索哈格大學醫院啟動了一項臨床試驗，以評估阿達木單抗治療成人患者白塞氏症相關葡萄膜炎的安全性和有效性。 注射劑用於治療白塞氏症，特別是對於無法耐受需要快速起效或高劑量的藥物或無法耐受口服藥物的患者。 透過注射給藥可以將藥物直接輸送到血流中，確保全身份佈。 治療行業的成長是由技術創新、疾病盛行率增加、醫療保健服務的改善以及對早期幹預和聯合治療方法的日益重視所推動的。 因此，在給藥途徑中，注射劑領域預計在預測期內將出現較高的複合年增長率。

依分銷管道劃分，市場分為醫院藥局、零售藥局等。 2022年，醫院藥局產業將主導市場。 醫院藥局透過確保用於治療白塞氏症的藥物的可用性、適當儲存、準備和配發，在白塞氏症的治療中發揮重要作用。 醫院藥房滿足白塞氏症住院患者和門診患者的需求，在整個治療過程中提供全面的藥物和支持。 除此之外，醫院數量的增加也支持了該行業的成長。 例如，根據美國醫院協會的數據，2022 年 10 月，美國約有 6,093 家醫院，由非營利組織以及州和地方政府營運的社區醫院組成。 因此，2022年，醫院在白塞氏症治療藥物市場中佔有很大佔有率。

為了更瞭解白塞病藥物的市場介紹，將市場分為北美（美國、加拿大等北美地區）、歐洲（德國、英國、法國、西班牙、義大利等歐洲地區）和亞太地區（根據世界其他地區（中國、日本、印度、亞太其他地區）和世界其他地區的全球影響力進行分析。 預計在預測期內，亞太地區的全球白塞氏症治療市場將以高複合年增長率成長。 在預測期內，有幾個因素正在推動市場成長，包括進行的臨床試驗數量的快速增加、可及性的提高以及醫療保健成本的多樣化。 例如，2023年12月，中國Ganzhou Hemay Pharmaceutical Co., Ltd.啟動了一項臨床試驗，研究Hemay005片劑對白塞氏症患者的療效和安全性。 此外，白塞氏症患者數量的增加也對市場成長產生正面影響。 該地區是主要罕見疾病宣傳項目和產品促銷活動的所在地。 因此，預計亞太地區在預測期內的複合年增長率將更高。

該市場營運的主要公司包括AbbVie, Eisai, Inos, Amgen, Mitsubishi Chemical Group, Bristol-Myers Squibb, Sanguin Biosciences, Takeda Pharmaceutical, Celltrion, Cardinal Health。

目錄

第一章市場介紹

  • 市場定義
  • 主要目標
  • 利害關係人
  • 限制

第二章研究方法或前提

  • 調查過程
  • 調查方法
  • 受訪者簡介

第三章市場總結

第 4 章執行摘要

第五章 COVID-19 對白塞氏症治療藥物市場的影響

第六章白塞氏症治療藥物市場收入，2020-2030

第七章依處理法進行市場分析

  • 皮質類固醇
  • 免疫抑制劑
  • 其他

第 8 章依給藥途徑進行的市場分析

  • 口頭
  • 注射
  • 其他

第 9 章依通路劃分的市場分析

  • 醫院藥房
  • 零售藥局
  • 其他

第10章區域市場分析

  • 北美
    • 美國
    • 加拿大
    • 其他北美地區
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區

第11章白塞氏症藥物市場動態

  • 市場驅動因素
  • 市場課題
  • 影響分析

第十二章白塞氏症治療藥物市場機會

第十三章白塞氏症治療藥物市場趨勢

第十四章供需分析

  • 需求方分析
  • 供給面分析

第 15 章價值鏈分析

第16章比賽場景

  • 競爭狀況
    • 波特五力分析

第十七章公司簡介

  • AbbVie Inc.
  • Eisai Co., Ltd.
  • Ainos Inc.
  • Amgen Inc.
  • Mitsubishi Chemical Group Corporation
  • Bristol-Myers Squibb Company
  • Sanguine Biosciences
  • Takeda Pharmaceutical Company Limited
  • CELLTRION INC.
  • Cardinal Health

第 18 條免責聲明

簡介目錄
Product Code: UMHE212676

Behcet's disease is a rare autoimmune disorder characterized by inflammation of blood vessels throughout the body, resulting in a wide range of symptoms. These may include recurrent oral ulcers, genital ulcers, skin lesions, eye inflammation, and joint pain. It can affect the gastrointestinal tract, central nervous system, and blood vessels. It's believed to involve a combination of genetic predisposition and environmental factors, such as infections or autoimmune triggers. A rising number of clinical trials and technological advancements are leading to the market's growth. Several other factors, such as rising research & development activities, rising healthcare expenditure, rising regulatory support, and a surge in government collaborations & partnerships are driving the behcet's disease therapeutics market globally.

The Behcet's Disease Therapeutics Market is expected to grow at a steady rate of around 5.1% owing to the growing prevalence of behcet's disease globally. For instance, according to the National Organization for Rare Disorders, Inc., behcet's disease occurs most frequently in the Middle East and Asia. Turkey has the highest prevalence rate; Japan, Korea, China, Iran, and Saudi Arabia also have high prevalence rates. The disorder is the leading cause of blindness in Japan. Several factors, including a rising number of clinical trials to find effective treatment, and rising investments in healthcare departments are driving the market's growth during the forecast period. Apart from this, accelerated diagnosis of behcet's disease therapeutics has resulted in higher demand for effective treatment procedures which are also driving this market of behcet's disease therapeutics at a steady rate.

Based on the treatment, the market is segmented into corticosteroids, immunosuppressive agents, and others. The immunosuppressive agents segment dominated the market in the year 2022 owing to the rising cases of severe Behcet's disease. Immunosuppressive agents are an important component of the treatment regimen for Behcet's disease, for patients who do not respond adequately to corticosteroids alone or who require long-term management to prevent recurrent flares. These medications work by suppressing the overactive immune response responsible for inflammation in Behcet's disease. Thus, among the treatments, the immunosuppressive agents segment held a significant market share in 2022.

Based on the route of administration, the market is segmented into oral, injectables, and others. The injectables segment is expected to grow with a high CAGR during the forecast period because of the rising number of clinical trials. For instance, in January 2023, Sohag University initiated a clinical trial to assess the safety and efficacy of adalimumab therapy for the treatment of Behcet's disease-related uveitis in adult patients at Sohag University Hospital. An injectable route of administration is utilized in Behcet's disease treatment, particularly for medications that require rapid onset of action, higher doses, or for individuals who cannot tolerate oral medications. Injectable administration allows for direct delivery of medications into the bloodstream, ensuring systemic distribution throughout the body. The growth of the treatment segment is driven by technological innovation, increasing disease prevalence, improved access to healthcare services, and a growing emphasis on early intervention and combination therapy approaches. Thus, the injectables segment among routes of administration is expected to witness a higher CAGR during the forecast period.

Based on distribution channel, the market is categorized into hospitals pharmacies, retail pharmacies, and others. The hospital pharmacy segment dominated the market in the year 2022. Hospital pharmacies play a crucial role in Behcet's disease treatment by ensuring the availability, proper storage, preparation, and dispensing of medications used in the management of this condition. Hospital pharmacies cater to the needs of both inpatients and outpatients receiving treatment for Behcet's disease, providing comprehensive pharmaceutical care and support throughout the treatment process. Apart from this, the growing number of hospital set-ups is also propelling segmental growth. For instance, according to the American Hospital Association, there were about 6,093 hospitals in the U.S. in October 2022, which comprises community hospitals run by non-profit organizations as well as by state and local governments. Thus, hospitals held a significant share of the behcet's disease therapeutics market in 2022.

For a better understanding of the market adoption of behcet's disease therapeutics, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with a high CAGR in the global behcet's disease therapeutics market in the forecast period. Several factors such as a surge in the number of clinical trials being performed, enhanced accessibility, and diversified healthcare costs are driving the market's growth during the forecast period. For instance, in December 2023, China-based Ganzhou Hemay Pharmaceutical Co., Ltd. initiated a clinical trial to study the efficacy and safety of Hemay005 tablets in patients with behcet's disease. Further, the increase in incidences of behcet's disease is also having a positive impact on the market's growth. There have been major awareness programs regarding rare diseases and product launches in the region. Thus, APAC is expected to witness a higher CAGR during the forecast period.

Some of the major players operating in the market include AbbVie Inc.; Eisai Co., Ltd.; Ainos Inc.; Amgen Inc.; Mitsubishi Chemical Group Corporation; Bristol-Myers Squibb Company; Sanguine Biosciences; Takeda Pharmaceutical Company Limited; CELLTRION INC.; Cardinal Health.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1.Market Definitions
  • 1.2.Main Objective
  • 1.3.Stakeholders
  • 1.4.Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1.Research Process of the Behcet's Disease Therapeutics Market
  • 2.2.Research Methodology of the Behcet's Disease Therapeutics Market
  • 2.3.Respondent Profile

3.MARKET SYNOPSIS

4.EXECUTIVE SUMMARY

5.IMPACT OF COVID-19 ON THE BEHCET'S DISEASE THERAPEUTICS MARKET

6.BEHCET'S DISEASE THERAPEUTICS MARKET REVENUE (USD BN), 2020-2030F

7.MARKET INSIGHTS BY TREATMENT

  • 7.1.Corticosteroids
  • 7.2.Immunosuppressive Agents
  • 7.3.Others

8.MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

  • 8.1.Oral
  • 8.2.Injectables
  • 8.3.Others

9.MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 9.1.Hospitals Pharmacies
  • 9.2.Retail Pharmacies
  • 9.3.Others

10.MARKET INSIGHTS BY REGION

  • 10.1.North America
    • 10.1.1.U.S.
    • 10.1.2.Canada
    • 10.1.3.Rest of North America
  • 10.2.Europe
    • 10.2.1.Germany
    • 10.2.2.U.K.
    • 10.2.3.France
    • 10.2.4.Italy
    • 10.2.5.Spain
    • 10.2.6.Rest of Europe
  • 10.3.Asia-Pacific
    • 10.3.1.China
    • 10.3.2.Japan
    • 10.3.3.India
    • 10.3.4.Rest of Asia-Pacific
  • 10.4.Rest of World

11.BEHCET'S DISEASE THERAPEUTICS MARKET DYNAMICS

  • 11.1.Market Drivers
  • 11.2.Market Challenges
  • 11.3.Impact Analysis

12.BEHCET'S DISEASE THERAPEUTICS MARKET OPPORTUNITIES

13.BEHCET'S DISEASE THERAPEUTICS MARKET TRENDS

14.DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1.Demand Side Analysis
  • 14.2.Supply Side Analysis

15.VALUE CHAIN ANALYSIS

16.COMPETITIVE SCENARIO

  • 16.1.Competitive Landscape
    • 16.1.1.Porters Fiver Forces Analysis

17.COMPANY PROFILED

  • 17.1.AbbVie Inc.
  • 17.2.Eisai Co., Ltd.
  • 17.3.Ainos Inc.
  • 17.4.Amgen Inc.
  • 17.5.Mitsubishi Chemical Group Corporation
  • 17.6.Bristol-Myers Squibb Company
  • 17.7.Sanguine Biosciences
  • 17.8.Takeda Pharmaceutical Company Limited
  • 17.9.CELLTRION INC.
  • 17.10.Cardinal Health

18.DISCLAIMER